The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...

New treatment builds on Pfizer’s migraine portfolio to further meet the needs of people living with this debilitating disease ...